What you'll learn in this expert session
Keratinocyte cancer (KC) is more common than all other forms of cancer, combined. Australia is particularly vulnerable and has the highest rate in the world. Extensive sun exposure and increasing age are the primary risk factors. Patients also tend to develop multiple lesions, which can be particularly burdensome. Emerging treatments, such as widefield radiation therapy, can target large areas of both cancer and pre-cancerous lesions with the goal of reducing the need for frequent interventions. This option holds promise for patients with severe disease who have exhausted other therapeutic options.
About the Expert
Dr Ian Porter
Dr Ian Porter is the Director of Radiation Oncology at Cabrini Health and is based at GenesisCare Cabrini in Melbourne, Australia. He is also a trials investigator with TROG and the NHMRC, with special interests in skin, gastrointestinal, lung and haematological malignancies. His other interests include stereotactic radiotherapy.
He was the first Radiation Oncologist in Australasia to use Brainlab gated stereotactic radiotherapy for treatment of liver tumours.
